Orion Portfolio Solutions LLC Sells 1,111 Shares of Innoviva, Inc. (NASDAQ:INVA)

Orion Portfolio Solutions LLC cut its position in Innoviva, Inc. (NASDAQ:INVA) by 1.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 79,389 shares of the biotechnology company’s stock after selling 1,111 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Innoviva were worth $1,533,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in INVA. Jane Street Group LLC lifted its stake in Innoviva by 46.4% in the 3rd quarter. Jane Street Group LLC now owns 136,361 shares of the biotechnology company’s stock valued at $2,633,000 after purchasing an additional 43,218 shares during the last quarter. Systematic Financial Management LP raised its stake in Innoviva by 4.7% in the third quarter. Systematic Financial Management LP now owns 1,979,073 shares of the biotechnology company’s stock valued at $38,216,000 after buying an additional 89,633 shares during the period. Walleye Capital LLC acquired a new stake in shares of Innoviva in the third quarter valued at approximately $214,000. Martingale Asset Management L P boosted its stake in shares of Innoviva by 0.7% during the 3rd quarter. Martingale Asset Management L P now owns 77,842 shares of the biotechnology company’s stock worth $1,503,000 after acquiring an additional 550 shares during the period. Finally, FMR LLC increased its holdings in shares of Innoviva by 8.2% during the 3rd quarter. FMR LLC now owns 10,119 shares of the biotechnology company’s stock worth $195,000 after acquiring an additional 771 shares during the last quarter. 99.12% of the stock is currently owned by institutional investors and hedge funds.

Innoviva Trading Up 0.2 %

Shares of Innoviva stock opened at $18.58 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.79 and a quick ratio of 1.64. The business has a fifty day simple moving average of $19.47 and a two-hundred day simple moving average of $18.41. Innoviva, Inc. has a 1 year low of $14.32 and a 1 year high of $21.28. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of 26.93 and a beta of 0.53.

Innoviva (NASDAQ:INVA) last issued its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.27 by ($0.25). Innoviva had a return on equity of 20.84% and a net margin of 18.31%. The firm had revenue of $89.51 million for the quarter. Research analysts forecast that Innoviva, Inc. will post 0.33 EPS for the current year.

About Innoviva

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.